International Journal of Molecular Sciences (Dec 2023)

The Effect of an Innovative Combination of Bergamot Polyphenolic Fraction and <i>Cynara cardunculus</i> L. Extract on Weight Gain Reduction and Fat Browning in Obese Mice

  • Saverio Nucera,
  • Federica Scarano,
  • Roberta Macrì,
  • Rocco Mollace,
  • Micaela Gliozzi,
  • Cristina Carresi,
  • Stefano Ruga,
  • Maria Serra,
  • Annamaria Tavernese,
  • Rosamaria Caminiti,
  • Annarita Coppoletta,
  • Antonio Cardamone,
  • Tiziana Montalcini,
  • Arturo Pujia,
  • Ernesto Palma,
  • Carolina Muscoli,
  • Francesco Barillà,
  • Vincenzo Musolino,
  • Vincenzo Mollace

DOI
https://doi.org/10.3390/ijms25010191
Journal volume & issue
Vol. 25, no. 1
p. 191

Abstract

Read online

Obesity is one of the world’s most serious public health issues, with a high risk of developing a wide range of diseases. As a result, focusing on adipose tissue dysfunction may help to prevent the metabolic disturbances commonly associated with obesity. Nutraceutical supplementation may be a crucial strategy for improving WAT inflammation and obesity and accelerating the browning process. The aim of this study was to perform a preclinical “proof of concept” study on Bergacyn®, an innovative formulation originating from a combination of bergamot polyphenolic fraction (BPF) and Cynara cardunculus (CyC), for the treatment of adipose tissue dysfunction. In particular, Bergacyn® supplementation in WD/SW-fed mice at doses of 50 mg/kg given orally for 12 weeks, was able to reduce body weight and total fat mass in the WD/SW mice, in association with an improvement in plasma biochemical parameters, including glycemia, total cholesterol, and LDL levels. In addition, a significant reduction in serum ALT levels was highlighted. The decreased WAT levels corresponded to an increased weight of BAT tissue, which was associated with a downregulation of PPARγ as compared to the vehicle group. Bergacyn® was able to restore PPARγ levels and prevent NF-kB overexpression in the WAT of mice fed a WD/SW diet, suggesting an improved oxidative metabolism and inflammatory status. These results were associated with a significant potentiation of the total antioxidant status in WD/SW mice. Finally, our data show, for the first time, that Bergacyn® supplementation may be a valuable approach to counteract adipose tissue dysfunction and obesity-associated effects on cardiometabolic risk.

Keywords